Skip to main content
Equibles
BIO logo

BIO · Bio-Rad Laboratories, Inc. · Webcasts, Transcripts & Audio

Track BIO — free

Use BIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$372.18 -12.22 (-3.18%) At close · Oct 30 Q2 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.95B
Shares
26.74M
Volume · Oct 30 183.13K Avg daily vol (3M) 254.36K

Bio-Rad Laboratories, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Bio-Rad Laboratories, Inc. (BIO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-11-10
Bio-Rad Laboratories, Inc. (BIO) November 10, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Bio-Rad Laboratories, Inc. (BIO) November 10, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-04
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-09
Bio-Rad Laboratories, Inc. (BIO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Bio-Rad Laboratories, Inc. (BIO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Positive tone Digital PCR Franchise Growth China Market Dynamics Middle East / Geopolitical Volatility
Revenue
$651.00M
▼ 0.1% YoY
Diluted EPS
$13.85
▲ 18.7% YoY
Gross margin
53.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Bio-Rad Laboratories, Inc. (BIO) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Bio-Rad Laboratories, Inc. (BIO) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Cautious tone Middle East Conflict Headwind Biopharma Stabilization Digital PCR / QX700 Platform
Revenue
$592.10M
▲ 1.1% YoY
Diluted EPS
$-19.55
▼ 953.7% YoY
Gross margin
52.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Positive tone 2026 guidance and long-term confidence Clinical diagnostics segment performance Gross margin pressure and operational execution
Revenue
$693.20M*
▲ 3.9% YoY
Gross margin
49.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Balanced tone Process chromatography Clinical Diagnostics and China reimbursement Geographic performance
Revenue
$653.00M
▲ 0.5% YoY
Diluted EPS
$-12.70
▼ 154.4% YoY
Gross margin
52.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript
Positive tone Process Chromatography Strength China Diagnostics Reimbursement Pressure ddPCR Portfolio Expansion
Revenue
$651.60M
▲ 2.1% YoY
Diluted EPS
$11.67
Gross margin
53.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
Balanced tone Tariffs and trade tensions China market dynamics Academic and government funding headwinds
Revenue
$585.40M
▼ 4.2% YoY
Diluted EPS
$2.29
▼ 83% YoY
Gross margin
52.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript
Positive tone Life Science segment softness 2025 outlook and gradual recovery China reimbursement change in diabetes testing
Revenue
$667.50M
▼ 2% YoY
Diluted EPS
$-25.57
▼ 310.6% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript
Balanced tone Process Chromatography Destocking Life Science Market Recovery Asia Pacific and China Headwinds
Revenue
$649.70M
▲ 2.8% YoY
Diluted EPS
$23.34
▲ 541.2% YoY
Gross margin
54.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
Balanced tone Life Science demand softness Clinical diagnostics strength Process chromatography destocking
Revenue
$638.50M
▼ 6.3% YoY
Diluted EPS
$-76.26
Gross margin
55.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
Balanced tone Life Science Market Weakness and Destocking Clinical Diagnostics Growth Gross Margin and Cost Actions
Revenue
$610.80M
▼ 9.8% YoY
Diluted EPS
$13.45
▲ 479.7% YoY
Gross margin
53.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript
Cautious tone Life Science and ddPCR weakness 2024 outlook and guidance Operational and cost management
Revenue
$681.20M
▼ 6.7% YoY
Diluted EPS
$12.14
▼ 56.3% YoY
Gross margin
53.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Earnings Call Transcript
Revenue
$632.12M
▼ 7.1% YoY
Diluted EPS
$3.64
Gross margin
53.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Call Transcript
Revenue
$681.11M
▼ 1.4% YoY
Diluted EPS
$-39.59
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Call Transcript
Revenue
$676.84M
▼ 3.3% YoY
Diluted EPS
$2.32
Gross margin
53.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Call Transcript
Revenue
$730.30M
▼ 0.3% YoY
Diluted EPS
$27.78
Gross margin
54.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Bio-Rad Laboratories, Inc. (BIO) Q3 2022 Earnings Call Transcript
Revenue
$680.80M
▼ 8.9% YoY
Diluted EPS
$-5.48
▼ 104.2% YoY
Gross margin
54.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Bio-Rad Laboratories, Inc. (BIO) Q2 2022 Earnings Call Transcript
Revenue
$691.10M
▼ 3.5% YoY
Diluted EPS
$-31.05
▼ 202.1% YoY
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Bio-Rad Laboratories, Inc. (BIO) Q1 2022 Earnings Call Transcript
Revenue
$700.06M
▼ 3.7% YoY
Diluted EPS
$-112.50
▼ 446.6% YoY
Gross margin
57.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Bio-Rad Laboratories, Inc. (BIO) Q4 2021 Earnings Call Transcript
Revenue
$732.80M
▼ 7.2% YoY
Diluted EPS
$-52.54
▼ 288.9% YoY
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Bio-Rad Laboratories, Inc. (BIO) Q3 2021 Earnings Call Transcript
Revenue
$747.05M
▲ 15.4% YoY
Diluted EPS
$130.02
▲ 197.9% YoY
Gross margin
58.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Bio-Rad Laboratories, Inc. (BIO) Q2 2021 Earnings Call Transcript
Revenue
$715.93M
▲ 33.4% YoY
Diluted EPS
$30.41
▼ 5.4% YoY
Gross margin
56.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Bio-Rad Laboratories, Inc. (BIO) Q1 2021 Earnings Call Transcript
Revenue
$726.80M
▲ 27.1% YoY
Diluted EPS
$32.46
▲ 42.9% YoY
Gross margin
55.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Bio-Rad Laboratories, Inc. (BIO) Q4 2020 Earnings Call Transcript
Revenue
$789.80M
▲ 26.5% YoY
Diluted EPS
$27.81
▲ 51.9% YoY
Gross margin
58.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Bio-Rad Laboratories, Inc. (BIO) Q3 2020 Earnings Call Transcript
Revenue
$647.26M
▲ 15.5% YoY
Diluted EPS
$43.64
Gross margin
56.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Bio-Rad Laboratories, Inc. (BIO) Q2 2020 Earnings Call Transcript
Revenue
$536.88M
▼ 6.2% YoY
Diluted EPS
$32.15
▲ 61.9% YoY
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Bio-Rad Laboratories, Inc. (BIO) Q1 2020 Earnings Call Transcript
Revenue
$571.64M
▲ 3.2% YoY
Diluted EPS
$22.72
▼ 20.9% YoY
Gross margin
55.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Bio-Rad Laboratories, Inc. (BIO) Q4 2019 Earnings Call
Revenue
$624.50M
▲ 1.2% YoY
Diluted EPS
$18.31
Gross margin
52.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–34 of 34 webcasts
Key facts CIK 12208 CUSIP 090572207 13F (30d) 147 filings 120 filers Visit website Investor relations